Drugs / FF21101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02454010 | Jan 2016 → Oct 2021 | cancer | Fujifilm Pharmaceuticals U.S.A., Inc. | Completed | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FF-21101 | “A Phase 1 Dose-escalation Study of Radio- Labeled Antibody, FF-21101(90Y) for the Treatment of Advanced Cancer” NCT02454010 ↗ |
| Known as | 90Y-FF-21101 | “Yttrium-90 FF-21101 (90Y-FF-21101) is a radiopharmaceutical that targets P-cadherin as a therapy against solid tumors.” PMID 39748726 ↗ Jan 2025 |
| Modality | Monoclonal antibody | “(90Y) radio-labeled FF21101 (therapeutic monoclonal antibody to P-cadherin expressed by the CDH3 gene)” NCT02454010 ↗ |
| Route | Intravenous | “25 mCi/m2 intravenously once every three cycles of 28 days” PMID 39748726 ↗ Jan 2025 |